Recently, I’ve noticed quite a few people are paying attention to the DCPLUS direction, which is pretty interesting.

I’ve always felt that bringing the “research → token → market validation” model on-chain is a match made in heaven.

The medical and scientific research sector is inherently special: high barriers to entry, strict regulation, a large market size, and very stable cash flow. It’s actually rare to see these four attributes combined.

The key is that once it’s integrated with on-chain solutions, it can leverage real RWA (Real World Asset) revenue—so it’s no longer just hot air. There’s real business support and the ability to channel tangible value back into the token economy.

But to be honest, most DeSci projects on the market right now are still at the conceptual stage, and very few are actually able to deliver and generate real-world value.